Journal of the National Cancer Institute Advance Access originally published online on June 17, 2009
JNCI Journal of the National Cancer Institute 2009 101(13):964; doi:10.1093/jnci/djp126
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© The Author 2009. Published by Oxford University Press.
CORRESPONDENCE |
Re: Tandem vs Single Autologous Hematopoietic Cell Transplantation for the Treatment of Multiple Myeloma: A Systematic Review and Meta-analysis
Affiliations of authors: Department of Stem Cell Transplantation and Cellular Therapy (SG), University of Texas, MD Anderson Cancer Center, Houston, TX; Blood and Marrow Transplant Program (DHV), Loyola University, Stritch School of Medicine, Chicago, IL; Department Hematology and Hematopoietic Cell Transplantation (AK) and Department of Medical Oncology and Therapeutics Research (GS), City of Hope Cancer Center, Los Angeles, CA; Department of Medicine, University of Pennsylvania, PA (ES); Bone Marrow Transplant Program, Roswell Park Cancer Institute, Buffalo, NY (PM); Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI (MCP)
Correspondence to: Marcelo C. Pasquini, MD, MS, Center for International Blood and Marrow Transplant Research 9200 W. Wisconsin Ave, CC5500, Milwaukee, WI 53226 (e-mail: mpasquin@mcw.edu).
| The first 10% of the full text of this article appears below. |
Kumar et al. (1) recently reported results of a meta-analysis of tandem vs single autologous hematopoietic cell transplantation (HCT) for patients with multiple myeloma. The authors should be commended for trying to address an important and topical issue regarding HCT for multiple myeloma. However, we disagree with their conclusions, which we believe